Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
HER2-positive breast cancers have poorer prognosis and are prime candidates for molecular-targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction. While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2012/415170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549599997329408 |
|---|---|
| author | Andrea L. A. Wong Soo-Chin Lee |
| author_facet | Andrea L. A. Wong Soo-Chin Lee |
| author_sort | Andrea L. A. Wong |
| collection | DOAJ |
| description | HER2-positive breast cancers have poorer prognosis and are prime candidates for molecular-targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction. While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies. In recent years, an array of promising and novel anti-HER2 therapeutic agents and their combinations have entered various stages of clinical development. However, questions remain on the optimal sequences of HER2-directed therapies and selection of patients for the most appropriate drug or combinations; incompletely defined mechanisms of trastuzumab action and resistance have also dampened the progress of more successful biomarker-driven treatment approaches. This paper summarizes existing preclinical and clinical evidence on the mechanisms of trastuzumab action and resistance and provides an up-to-date overview of novel HER2-directed therapies in clinical development. |
| format | Article |
| id | doaj-art-9f6047f336174a31833e2a39ee51c2ae |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-9f6047f336174a31833e2a39ee51c2ae2025-02-03T06:10:57ZengWileyInternational Journal of Breast Cancer2090-31702090-31892012-01-01201210.1155/2012/415170415170Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerAndrea L. A. Wong0Soo-Chin Lee1Department of Haematology-Oncology, National University Cancer Institute, National University Health System, 119228, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, National University Health System, 119228, SingaporeHER2-positive breast cancers have poorer prognosis and are prime candidates for molecular-targeted therapy because they are driven by the unique mechanism of HER2 oncogene addiction. While anti-HER2 agents such as trastuzumab and lapatinib are integral to the treatment of HER2-positive breast cancer, intrinsic and secondary resistance pose a significant challenge, underscoring the need to develop novel anti-HER2 therapies. In recent years, an array of promising and novel anti-HER2 therapeutic agents and their combinations have entered various stages of clinical development. However, questions remain on the optimal sequences of HER2-directed therapies and selection of patients for the most appropriate drug or combinations; incompletely defined mechanisms of trastuzumab action and resistance have also dampened the progress of more successful biomarker-driven treatment approaches. This paper summarizes existing preclinical and clinical evidence on the mechanisms of trastuzumab action and resistance and provides an up-to-date overview of novel HER2-directed therapies in clinical development.http://dx.doi.org/10.1155/2012/415170 |
| spellingShingle | Andrea L. A. Wong Soo-Chin Lee Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer International Journal of Breast Cancer |
| title | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| title_full | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| title_fullStr | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| title_full_unstemmed | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| title_short | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| title_sort | mechanisms of resistance to trastuzumab and novel therapeutic strategies in her2 positive breast cancer |
| url | http://dx.doi.org/10.1155/2012/415170 |
| work_keys_str_mv | AT andrealawong mechanismsofresistancetotrastuzumabandnoveltherapeuticstrategiesinher2positivebreastcancer AT soochinlee mechanismsofresistancetotrastuzumabandnoveltherapeuticstrategiesinher2positivebreastcancer |